Is this diagnostics firm built for scale?
Exact Sciences is a biotechnology company focused on cancer-related diagnostics. It develops and sells testing solutions used to detect and manage disease. The business is built around delivering diagnostic information through lab testing workflows rather than selling traditional therapeutics. At roughly USD 20 billion in market value, it sits at a scale where financing choices start to matter as much as product adoption.
Can revenue growth offset persistent losses?
FundamentalsIn 2023 financials reported in USD, revenue reached about USD 2.5 billion, up 19.9% year over year, alongside EBIT of roughly USD 78 million. Profitability ratios over the trailing period remained negative, with a -6.35% operating margin and a -6.40% net profit margin, while gross margin sat at 69.69%.
On the balance sheet, cash of about USD 605 million stands against just USD 29 million of total debt. Depreciation and amortization was roughly USD 92 million, with capital spending of about USD 124 million, and the cash flow proxy for the period came in near USD 30 million.
Does the market price ignore negative value?
DCF / MultiplesThe current price is shown as USD 0.00. The DCF fair value range runs from USD -2.83 at the lower end to USD -5.37 at the midpoint and USD -7.89 at the upper end. The stock also trades at 6.17 times trailing sales, a pricing level that typically assumes meaningful value beyond today’s DCF output.
Cash strength, profit weakness
TakeawayThe balance sheet looks unusually light on debt. Cash provides time, but it does not replace profits. The business needs margins to turn sustainably positive. If losses linger, valuation support can stay fragile.